BioLineRx to Report First Quarter 2024 Results on May 28, 2024

Company Overview - BioLineRx Ltd. is a commercial stage biopharmaceutical company focused on developing life-changing therapies in oncology and rare diseases [4] - The company's first approved product is APHEXDA® (motixafortide), indicated for stem cell mobilization for autologous transplantation in multiple myeloma in the U.S. [4] - BioLineRx is advancing a pipeline of investigational medicines targeting sickle cell disease, pancreatic cancer, and other solid tumors [4] Financial Results Announcement - BioLineRx will release its unaudited financial results for the quarter ended March 31, 2024, on May 28, 2024, before U.S. markets open [1] - A conference call will be held at 8:30 a.m. EDT featuring remarks by CEO Philip Serlin [2] Conference Call Access - To access the conference call, dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally [3] - A live webcast and replay will be available on the company's website, with a replay accessible approximately two hours after the live call [3]